Loading the latest PSX data…
Loading the latest PSX data…
Sanofi-Aventis Pakistan Limited
0.00 (0.00%) today
Market closed, last update Nov 16, 2026 6:09 AMThe Sanofi-Aventis Pakistan share price was Rs 870.00 (0.00%) at the last PSX update (Nov 16, 2026 6:09 AM). SAPL is a pharmaceuticals stock with a market value of Rs 8.4bn.
Price limits (circuit breakers)
804.7550% up the range935.25
+1.5% over 5 years
Monthly closing prices from the PSX Data Portal, since 2003. Earlier prices are adjusted for bonus shares and splits (about 10% bonus or ex-dividend fall, 2013-04) so the line shows the value of one original share.
| Measure | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Sales growth | +16.9% | +12.6% | −2.7% | – |
| Profit growth | −81.6% | +83.7% | +218.4% | – |
| EPS growth | −81.6% | +83.7% | +218.5% | – |
| Net margin | 0.9% | 5.7% | 3.5% | 1.1% |
| Measure | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 |
|---|---|---|---|---|
| Sales growth | +29.0% | – | – | – |
| Profit growth | +1,843.7% | – | – | – |
| EPS growth | +1,847.2% | – | – | – |
| Net margin | 8.1% | -3.1% | -7.5% | 0.5% |
| Line item | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Sales | Rs 18.6bn | Rs 15.9bn | Rs 14.1bn | Rs 14.5bn |
| Profit after tax | Rs 167m | Rs 906m | Rs 493m | Rs 155m |
| Earnings per share (Rs) | 17.29 | 93.93 | 51.12 | 16.05 |
| Line item | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 |
|---|---|---|---|---|
| Sales | Rs 5.8bn | Rs 5.3bn | Rs 4.8bn | Rs 4.5bn |
| Profit after tax | Rs 469m | Rs -165m | Rs -357m | Rs 24m |
| Earnings per share (Rs) | 48.68 | -17.13 | -37.03 | 2.50 |
| Line item | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Gross margin | 26.2% | 26.0% | 27.0% | 25.7% |
| Net margin | 0.9% | 5.7% | 3.5% | 1.1% |
| EPS growth | -81.6% | 83.7% | 218.5% | -74.7% |
| PEG | -0.68 | 0.11 | 0.07 | -0.69 |
Rupee amounts from PSX filings (thousands converted to Rs m/bn). Data by Capital Stake via the PSX Data Portal; standardised, so it can differ from the annual report. Latest quarter (Q3 2023) EPS rose 1,847.2% from the same quarter a year earlier.
| Measure | SAPL | Sector median | Reading |
|---|---|---|---|
| P/E | – | 12.5 | – |
| Dividend yield | – | 5.1% | – |
| Net margin | 0.9% | 9.4% | Below peers |
| EPS growth | −81.6% | +34.5% | Below peers |
| 1-year return | – | −14.8% | – |
Sector P/E check. At the sector's median P/E of 12.5, last year's EPS of Rs 17.29 would price SAPL at about Rs 216.51 (−75% from today). A rough yardstick only: sectors hold very different businesses, and the market prices future profits, not last year's.
Estimate a fair value for SAPL (Graham, Lynch, DCF)SAPL pivot levels
Ratios as published on the PSX Data Portal (standardised by Capital Stake), latest financial year on the right.
Work out your SAPL dividend income after tax
PSX quotes payouts as a percentage of face value; cash per share assumes the usual Rs 10 face value. You get the dividend if you own the shares before the books close.
Market value
13th of 18
Rs 8.4bn
EPS growth
15th of 15
-81.6%
Net margin
15th of 16
0.9%
| GLAXOGlaxoSmithKline Pakistan Limited | Rs 107.1bn | −0.57% | 9.8 | 6.1% | −14.9% | 90 |
| ABOTAbbott Laboratories (Pakistan) Limited | Rs 97.9bn | +0.52% | 10.5 | 4.4% | −6.9% | 83 |
| HALEONHaleon Pakistan Limited | Rs 81.6bn | +0.16% | 12.5 | 3.6% | −14.8% | 69 |
| HINOONHighnoon Laboratories Limited | Rs 50.8bn | +0.37% | 12.4 | 5.4% | −14.0% | 82 |
| SEARLThe Searle Company Limited | Rs 46.6bn | −0.39% | 12.0 | – | −24.6% | 53 |
| AGPAGP Limited | Rs 43.8bn | −0.13% | 24.5 | 5.1% | −16.1% | 50 |
| HPLHoechst Pakistan Limited | Rs 38.5bn | −0.35% | 11.0 | 6.9% | −2.3% | – |
| FEROZFerozsons Laboratories Limited | Rs 15.8bn | −1.49% | 22.9 | 1.6% | −7.1% | 40 |
| CPHLCiti Pharma Ltd. | Rs 14.5bn | −0.21% | 17.8 | – | −22.6% | 33 |
| GSKCHGlaxoSmithKline Consumer Healthcare | Rs 14.1bn | −3.13% | – | – | – | – |
| MACTERMacter International Limited | Rs 12.0bn | +3.36% | 18.8 | – | −26.7% | 26 |
| BFBIOBF Biosciences Limited | Rs 11.9bn | −0.83% | 18.2 | – | −10.8% | 49 |
| SAPLThis stock · Sanofi-Aventis Pakistan Limited | Rs 8.4bn | 0.00% | – | – | – | – |
| OTSUOtsuka Pakistan Limited | Rs 5.4bn | −1.06% | 10.9 | – | +33.5% | 65 |
| LIVENLiven Pharma Limited | Rs 4.4bn | +9.99% | – | – | −18.9% | 9 |
Swipe the table sideways for more columns.
No director or substantial-shareholder trades in SAPL read from PSX notices yet.
Read automatically (OCR) from the disclosure images companies file with PSX under Regulation 5.6.1(d). A digit can be misread, so check the original notice before relying on a figure. Value = shares × price. Not investment advice. All PSX insider trades
The Company was incorporated in Pakistan in 1967 as a Public Limited Company under Companies Act, 1913 (now Companies Act, 2017). The Company is a subsidiary of Sanofi Foreign Participations B.V. registered in Netherlands. The ultimate parent of the Company is Sanofi S.A., France. The Company is engaged in the manufacturing, selling and trading of pharmaceutical and related products.
Data: PSX Data Portal (Nov 16, 2026 6:09 AM); company data refreshed 16 Nov; daily bars from PSX market summaries; five-year record from danioPSX research. Logos are trademarks of their owners. Not a recommendation to buy or sell SAPL. Official PSX page for SAPL